无体外循环超低潮气量通气治疗COVID-19中重度ARDS的开放标签随机对照试验:VT4COVID研究方案
VT4COVID是一项多中心、开放标签、随机对照优效性试验,纳入COVID-19相关轻至重度ARDS成人患者,随机分为保护性通气组(潮气量6 mL/kg PBW)和超低潮气量通气组(4 mL/kg PBW),主要结局为90天全因死亡与60天无呼吸机天数的复合评分。
要点
- 超低潮气量通气(4 mL/kg PBW)无需体外循环,可能减少呼吸机相关肺损伤。
- 研究纳入PaO2/FiO2≤150 mmHg且机械通气<48小时的COVID-19 ARDS患者。
- 主要结局为90天全因死亡与60天无呼吸机天数的复合评分。
核心结论
- 超低潮气量通气(4 mL/kg PBW)无体外循环可能是降低COVID-19相关ARDS死亡率和机械通气时间的可行选择。
研究设计与样本
- 多中心、前瞻性、开放标签、随机对照优效性试验,1:1平行分组,按招募中心分层,随机区组大小为4和6,意向性分析。
- 纳入ICU内COVID-19相关轻至重度ARDS成人患者,PaO2/FiO2≤150 mmHg且侵入性机械通气<48小时。
主要发现
- 原文为研究方案,未报告试验结果。
关键数值与推荐
- 对照组潮气量6 mL/kg预测体重(PBW),干预组潮气量4 mL/kg PBW。
- 主要结局为基于90天全因死亡(优先标准)和入组后60天无呼吸机天数的复合评分。
临床怎么用
- 为COVID-19相关中重度ARDS患者提供无体外循环的超低潮气量通气策略的循证依据。
局限性
- 开放标签设计可能引入偏倚。
- 研究方案尚未报告结果,结论待验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute respiratory distress syndrome (ARDS) is a severe complication of COVID-19 pneumonia, with a mortality rate amounting to 34-50% in moderate and severe ARDS, and is associated with prolonged duration of invasive mechanical ventilation. Such as in non-COVID ARDS, harmful mechanical ventilation settings might be associated with worse outcomes. Reducing the tidal volume down to 4 mL kg-1 of predicted body weight (PBW) to provide ultra-low tidal volume ventilation (ULTV) is an appealing technique to minimize ventilator-inducted lung injury. Furthermore, in the context of a worldwide pandemic, it does not require any additional material and consumables and may be applied in low- to middle-income countries. We hypothesized that ULTV without extracorporeal circulation is a credible option to reduce COVID-19-related ARDS mortality and duration of mechanical ventilation. METHODS: The VT4COVID study is a randomized, multi-centric prospective open-labeled, controlled superiority trial. Adult patients admitted in the intensive care unit with COVID-19-related mild to severe ARDS defined by a PaO2/FiO2 ratio ≤ 150 mmHg under invasive mechanical ventilation for less than 48 h, and consent to participate to the study will be eligible. Patients will be randomized into two balanced parallels groups, at a 1:1 ratio. The control group will be ventilated with protective ventilation settings (tidal volume 6 mL kg-1 PBW), and the intervention group will be ventilated with ULTV (tidal volume 4 mL kg-1 PBW). The primary outcome is a composite score based on 90-day all-cause mortality as a prioritized criterion and the number of ventilator-free days at day 60 after inclusion. The randomization list will be stratified by site of recruitment and generated using random blocks of sizes 4 and 6. Data will be analyzed using intention-to-treat principles. DISCUSSION: The purpose of this manuscript is to provide primary publication of study protocol to prevent selective reporting of outcomes, data-driven analysis, and to increase transparency. Enrollment of patients in the study is ongoing. TRIAL REGISTRATION: ClinicalTrials.gov NCT04349618 . Registered on April 16, 2020.
引用
- Richard JC, Yonis H, Bitker L, et al. Open-label randomized controlled trial of ultra-low tidal ventilation without extracorporeal circulation in patients with COVID-19 pneumonia and moderate to severe ARDS: study protocol for the VT4COVID trial. Trials. 2021. PMID: 34635128. doi:10.1186/s13063-021-05665-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。